Which of the following statements describes a potential adverse interaction when fenofibrate is used with high-intensity statins?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

The main concept being tested is the potential muscle toxicity when fenofibrate is used with high-intensity statins. Both drugs can cause muscle symptoms on their own, but together—especially with high-dose statins—the risk of myopathy increases and can progress to rhabdomyolysis in rare cases. This heightened risk comes from additive effects on muscle cells and, in some cases, pharmacokinetic interactions that raise statin exposure. Fenofibrate generally carries a lower risk of this interaction than gemfibrozil, but the possibility remains, so clinicians monitor for muscle symptoms and may adjust the statin dose or choose an alternative strategy if concerns arise. While hepatotoxicity and GI symptoms can occur with these drugs individually, they aren’t the primary interaction here, and stroke or MI risk isn’t an interaction between these medications.